On March 20, 2023 Convergent Therapeutics Inc., a clinical-stage biotechnology company, reported the title of an upcoming clinical trial plenary oral presentation evaluating its lead asset, CONV01-α (225Ac-J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225 (225Ac), which will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 taking place in Orlando, April 14 – 19 (Press release, Convergent Therapeutics, MAR 20, 2023, View Source [SID1234629059]). The plenary talk entitled "Phase I dose-escalation study of fractionated dose 225Ac-J591 for metastatic castration resistant prostate cancer" will be presented by Dr. Jones T. Nauseef, Assistant Professor of Medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Abstract Title: Phase I dose-escalation study of fractionated dose 225Ac-J591 for metastatic castration resistant prostate cancer
Date and Time: Monday April 17, 2023, from 11:45 AM – 12:00 PM
Location: W Hall A2-3 – Convention Center
Session Category: Clinical Trials Plenary Session
Session Title: Promising Novel Antitumor Strategies in Early Phase Clinical Trials
Presentation Number: CT014
Presenter: Dr. Jones T. Nauseef, Assistant Professor of Medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine